1. Home
  2. |Insights
  3. |2024 ACAMS The Assembly Hollywood Conference

2024 ACAMS The Assembly Hollywood Conference

Event | 04.08.24 - 04.10.24

Address

The Diplomat Beach Resort Hollywood, Curio Collection by Hilton

3555 S Ocean Dr
Hollywood, FL 33019

The Anti-Money Laundering Act of 2020 (AMLA) and subsequent amendments created a new FinCEN Whistleblower Program specifically to report potential Bank Secrecy Act, sanctions, and money laundering violations. Today, the whistleblower provisions are an important consideration as part of an institution’s BSA/AML and sanctions compliance.

Join Crowell partner Anand Sithian for an insightful panel at the 2024 Association of Certified Anti-Money Laundering Specialists (ACAMS) Assembly Hollywood Conference, where the panel will discuss this new program, FinCEN’s new Office of the Whistleblower, and how institutions can assess the adequacy of their internal reporting mechanisms to further ensure regulatory compliance. 

The panel will be moderated by Kelly Cooper, CAMS, Vice President, Global Financial Crimes Compliance, JPMorgan Chase & Co., and will include fellow panelist Matthew Haslinger, Executive Vice President, Chief BSA/AML/OFAC Officer, M&T Bank.

For more information on Crowell’s thought leadership on the FinCEN whistleblower program, please visit: Treasury eyes bank whistleblowers as it steps up sanctions enforcement; DOJ official: People ‘drawing the right conclusions’ on national security focus; One Year Later: Addressing Whistleblower Risks Under the AMLA

For more information, please visit these areas: Financial Services, White Collar and Regulatory Enforcement

Participants

Insights

Event | 12.04.25

ACI 30th Annual Conference on Drug & Medical Device Litigation

Dan Campbell with Speak on the panel "Mastering MDL Case Management: What Proposed Rule 16.1 Really Means for Consolidated Litigation."
Rule 16.1 attempts to guide early case management in MDLs, impacting litigation pace and costs. Permissive language like “should” instead of “must”, could lead to inconsistent applications. This panel will explore the rule’s anticipated impact and implications for procedures.